UNFAVORABLE GENETICS IMPACT MRD RESPONSE TO VENETOCLAX RITUXIMAB RETREATMENT IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL): PHASE 3 MURANO SUBSTUDY

2021 
    • Correction
    • Source
    • Cite
    • Save
    • Machine Reading By IdeaReader
    0
    References
    0
    Citations
    NaN
    KQI
    []